Biotech Stock Ratings
HC Wainwright Reiterates Buy Ratings on Four Biotechs and Sell on Sarepta
Anonymous
HC Wainwright maintained bullish stances on four biotechs while staying bearish on one. The firm reiterated Buy ratings on Verastem, Monte Rosa Therapeutics, Vanda Pharmaceuticals, and CervoMed with price targets of $18, $25, $20, and $25, respectively. HC Wainwright kept a Sell rating on Sarepta Therapeutics with a $5 price target.
CervoMed saw particular confidence from the firm after neflamapimod advances. A new 50-milligram tablet formulation supports twice-daily dosing, and the FDA removed a plasma-exposure limit that previously constrained the drug. Better manufacturing processes also lower production risk and could extend patent protection into the early 2040s.
Five Biotech Ratings Across the Board
HC Wainwright & Co. delivered a mixed outlook across its biotech coverage. Verastem keeps a Buy rating and $18 target. Monte Rosa Therapeutics and Vanda Pharmaceuticals both hold $25 and $20 price targets with Buy ratings, respectively. CervoMed rounds out the bullish camp at $25. Only Sarepta draws a Sell call at $5, signaling skepticism about the company's near-term prospects.
CervoMed Drug Formulation Moves Forward Faster
CervoMed's neflamapimod candidate hit a milestone with tablet development. The new 50-milligram formulation delivers drug exposure suited to twice-daily dosing, making it more convenient than current options. HC Wainwright cited this as support for Buy conviction, noting it opens doors to broader patient use and simpler dosing schedules.
Regulatory wins stack in CervoMed's favor. The FDA dropped a prior plasma-exposure limit that had restricted dosing flexibility. Manufacturing improvements cut production costs and risk. These changes could allow patent claims extending exclusivity into the early 2040s — giving the company years of protected revenue if the drug succeeds in trials.
Sarepta Faces Headwinds Despite Gene Therapy Advances
Sarepta Therapeutics stands alone with a Sell rating and $5 price target from HC Wainwright. The bearish call contrasts sharply with the firm's bullish stance on peers. Sarepta has faced execution challenges and market pressures that weigh on HC Wainwright's outlook, even as the company pursues gene therapy treatments for rare muscle disorders.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
6
Reach
17
A
AnonymousAuthor
